Charles River Laboratories Intl. Inc vs Warner Music Group Corp — how do they compare? Charles River Laboratories Intl. Inc trades at $301.79 (market cap $14.23B), while Warner Music Group Corp trades at $28.72 (market cap $15.12B). The key difference: Charles River Laboratories Intl. Inc and Warner Music Group Corp are close in size by market cap, and Warner Music Group Corp pays a 2.77% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Warner Music Group Corp for 96 Days on average.
| CRL | WMG | |
|---|---|---|
Market Cap | $14.23B | $15.12B |
Volume | 1,176,885 | 2,966,414 |
Sector | Health | Media |
52-Week High | $310.77 | $34.72 |
52-Week Low | $149.93 | $23.65 |
Typical Hold Time | 33 Days | 96 Days |
Enterprise Value | $17.06B | $19.42B |
Dividend Yield | — | 2.77% |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $301.79, up 0.5% with strong analyst support (73% buy ratings) and a $305.50 consensus target. The stock shows bullish technical momentum above key support levels, though fundamentals reveal challenges with negative net income margins (-5.96%) and elevated P/E ratio (684.85). Recent quarterly earnings beats and a new 2030 growth strategy provide optimism, but profitability concerns persist amid flat revenue trends.
The outlook balances near-term technical strength against fundamental headwinds. Investment opportunity lies in execution of the 5-7% growth target and $300M savings plan, while risks include sustained negative profitability, high debt levels ($2.24B), and margin pressure. Current price near resistance at $304 suggests limited upside without fundamental improvement.
Warner Music Group (WMG) trades at $28.72, up 1.99% today, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating EPS estimates, and maintains a robust gross profit margin of 45.77%. Recent news highlights strategic AI partnerships and licensing renewals, signaling growth initiatives. Revenue has grown from $5.9B in 2022 to $6.7B in 2025, with a projected increase to $7.3B in 2026.
The outlook for WMG is positive, driven by earnings beats, analyst optimism, and AI-driven content curation opportunities. Key risks include competitive pressures in the music industry and execution challenges amid leadership changes. The consensus price target of $39.50 implies significant upside, but investors should monitor margin trends and competitive dynamics.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →Warner Music Group is the third largest of the three major global record labels, with Vivendi's Universal Music in first and Sony Music in second. Warner's larger segment, recorded music, consists of iconic labels like Atlantic Records, Warner Records, and Parlophone Records and popular artists such as Ed Sheeran, Cardi B, Dua Lipa, and Blake Shelton. Warner Chappell, the firm's publishing arm, is the home to over 65,000 composers and songwriters with over a million copyrights represented. Warner is controlled by Access Industries, which owns an 84% economic interest and 99% of voting rights.
Read more on WMG →